- SHINE Technologies signed a supply agreement with C-Ray Therapeutics, appointing it as the exclusive distributor of n.c.a. Lu-177 in mainland China.
- The partnership aims to improve access to radioisotopes and support radiopharmaceutical development through integrated manufacturing and distribution services.
SHINE Technologies has entered into a supply agreement with C-Ray Therapeutics, establishing the China-based company as its exclusive distribution partner for non-carrier-added lutetium-177 (n.c.a. Lu-177) across mainland China, with certain pre-existing partnerships excluded. The agreement focuses on expanding access to radiopharmaceutical materials for developers and healthcare institutions in the region.
Under the terms of the agreement, C-Ray will distribute SHINE’s Lu-177 to Chinese radiopharmaceutical developers, biotechnology companies, and healthcare providers. The company will also provide downstream contract manufacturing services, including isotope conjugation, fill-and-finish, and quality control, through its 28,000-square-meter facility in Chengdu.
Lu-177 is widely used in targeted radiopharmaceutical therapies, with applications in prostate cancer, neuroendocrine tumors, and other oncology indications. The partnership is intended to address supply constraints in China by combining SHINE’s isotope production capabilities with C-Ray’s local infrastructure for distribution and manufacturing.
SHINE will supply Lu-177 from its Cassiopeia facility in North America, with materials meeting both U.S. and Chinese regulatory standards. The agreement also includes support for regulatory processes through China’s National Medical Products Administration (NMPA), facilitating access for domestic developers.
“By combining C-Ray’s integrated development and manufacturing platform with our large-scale isotope production, we can help advance pipeline innovation and expand patient access to life-saving targeted radioligand therapies.”
Greg Piefer, Founder and CEO of SHINE Technologies
